Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia 2Philadelphia Chromosome 1Neoplasms 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Muscle Weakness 1Multiple Myeloma 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Hairy Cell 1Leukemia, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Burkitt Lymphoma 1

Interventions

Imatinib Mesylate 14Dasatinib 5nilotinib 4bosutinib 4Cyclophosphamide 4fludarabine 3Vincristine 3Methotrexate 3Dexamethasone 3Cytarabine 3peginterferon alfa-2a 2fludarabine phosphate 2asciminib 2Prednisone 2Daunorubicin 2Azacitidine 2Acetaminophen 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2venetoclax 1thymoglobulin 1ponatinib 1olverembatinib 1flumatinib 1blinatumomab 1Whole-Body Irradiation 1Tyrosine Kinase Inhibitors 1Tacrolimus 1Rituximab 1Prednisolone 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Philadelphia Chromosome × Magnetic Resonance Imaging × Other hematologic neoplasm × Clear all
NCT03448393 2025-06-04

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
54 enrolled 24 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Philadelphia Chromosome, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡